These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28627469)

  • 1. Modeling and comparison of release profiles: Effect of the dissolution method.
    Cascone S
    Eur J Pharm Sci; 2017 Aug; 106():352-361. PubMed ID: 28627469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration.
    Li ZQ; Tian S; Gu H; Wu ZG; Nyagblordzro M; Feng G; He X
    AAPS PharmSciTech; 2018 May; 19(4):1882-1893. PubMed ID: 29663288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z; Fassihi R
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the physiological variability of fasted gastric pH and tablet retention time on the variability of in vitro dissolution and simulated plasma profiles.
    Kovačič NN; Pišlar M; Ilić I; Mrhar A; Bogataj M
    Int J Pharm; 2014 Oct; 473(1-2):552-9. PubMed ID: 25064726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical Product Lead Optimization for Better In vivo Bioequivalence Performance: A case study of Diclofenac Sodium Extended Release Matrix Tablets.
    Shahiwala A; Zarar A
    Curr Drug Deliv; 2018; 15(5):705-715. PubMed ID: 29165078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report: in vitro dissolution studies of different brands of sustained release diclofenac sodium matrix tablet available in Bangladesh.
    Abdullah MD; Bepary S; Rouf AS
    Pak J Pharm Sci; 2008 Jan; 21(1):70-7. PubMed ID: 18166523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of dissolution medium agitation on release profiles of sustained-release tablets.
    Paulo ; Sousa Lobo JM
    Drug Dev Ind Pharm; 2001 Sep; 27(8):811-7. PubMed ID: 11699832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of gastro intestinal sustained release tablet formulation containing acryl-EZE and pH-dependent swelling HPMC K 15 M.
    Lamoudi L; Chaumeil JC; Daoud K
    Drug Dev Ind Pharm; 2012 May; 38(5):515-20. PubMed ID: 21978389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.
    Espíndola B; Bortolon FF; Pinto JMO; Pezzini BR; Stulzer HK
    AAPS PharmSciTech; 2018 Oct; 19(7):2866-2874. PubMed ID: 29934804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug--an in vitro and an in vivo study.
    M K; Sistla R; Shastri NR
    Drug Deliv; 2015 May; 22(3):418-26. PubMed ID: 24471823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions.
    Skripnik KKS; Riekes MK; Pezzini BR; Cardoso SG; Stulzer HK
    AAPS PharmSciTech; 2017 Jul; 18(5):1785-1794. PubMed ID: 27800567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution parameters for sodium diclofenac-containing hypromellose matrix tablet.
    Mourão SC; da Silva C; Bresolin TM; Serra CH; Porta V
    Int J Pharm; 2010 Feb; 386(1-2):201-7. PubMed ID: 19941944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of formulation on the dissolution profile of diclofenac sodium tablets.
    De Castro WV; Pires MA; Oliveira MA; Vianna-Soares CD; Nunan EA; Pianetti GA; Moreira-Campos LM; De Castro WV; Mertens-Talcott SU; Derendorf H
    Drug Dev Ind Pharm; 2006 Oct; 32(9):1103-9. PubMed ID: 17012123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.